New Delhi (NVI): Bharat Biotech’s Covid-19 vaccine- Covaxin has now been allowed for restricted use in emergency situation in public interest, the Central Government said today.
Bharat Biotech’s indigenously developed Covaxin is out of the “clinical trial mode”, as per the Government.
“Covaxin is now allowed for restricted use in emergency situation in public interest. This has taken the authorization for Covaxin to the next level, that is, the same level at which Covishield has been operating. The same licensure now applies to both the vaccines,” Dr VK Paul, NITI Aayog member (Health) said during a press briefing today.
Dr Paul further said that there has been an impressive speeding up of the COVID-19 vaccination programme over the last 10 days. “Through the participation of the public and private sectors both, working as one system, the nation has enhanced vaccine coverage phenomenally,” he added.
Pertinent to mention here that the central drug panel’s decision is based on the interim efficacy data, the regulator has asked Bharat Biotech to keep providing it data from its phase 3 trials.